Introduction
Increased concentrations of low-density-lipoprotein (LDL)-cholesterol (LDL-C) and lipoprotein a (Lp(a)) are scientifically accepted, independent risk factors for the development of atherosclerosis and its complications, such as myocardial infarction, stroke or peripheral arterial disease [1] . With industrialisation, a severe change in physical activity (less movement e.g. in sedentary activities) and nutrition patterns (high-calorie and high-fat diet) is observed in industrialized countries.
Increased inactivity and unbalanced nutrition in part are responsible of causing metabolic syndrome even in the younger population, leading to for example, myocardial infarction, which is no longer a phenomenon of ageing [2, 3] . Also, the lipid profiles associated with these changes in metabolism are, in absence of diabetes, mostly those of type IIa/IIb Frederickson's hyperlipoproteinaemia or an increase of LDL-C in combination with Lp(a) hyperlipidaemia, respectively. A large number of randomised studies have found that a reduction in LDL-C, especially by statins, is connected to a significant reduction of additional cardiovascular events of the respective patients (secondary prevention) [4] . Statins were also shown to prevent cardiovascular events in patients with hyperlipidaemia all together [5] . In these studies, next to statins, other lipid-lowering medication, such as nicotinic acid, was employed.
Evidence of an advantage of a combined application of statins and nicotinic acid in preventing cardiovascular events over statin monotherapy is not compelling [6] . If elevated Lp(a)-concentrations are responsible, therapy options are still very limited. Statins have only a small impact on Lp(a)-levels.
Currently, no medication licensed in Europe is able to effectively reduce Lp(a)-concentrations with a long-lasting impact. The clinical effects of the Lp(a)-reduction achieved by nicotinic acid have been disputed and are connected to major adverse effects [7] . Following negative study outcomes, nicotinic acid was withdrawn from the European markets. Therefore, the only effective therapy available today is chronic lipid apheresis (LA) treatment in weekly intervals. For this extracorporeal method, it was recently shown that the high rate of cardiovascular events can be reduced by at least 78% under chronic LA treatment [8, 9] . Broader usage of statin therapy is limited by the occurrence of adverse effects, such as myopathies including rhabdomyolysis or elevated liver function tests, leading in most of the affected cases to cancellation of statin therapy. While a large variety of statins exists, which in part are metabolised very differently (e.g. Cytochrome P450 3A4, glucuronidation), the aforementioned adverse effects cannot be avoided by a change in statin type in all cases [10] . Beyond the outlined options, there exists a clear need for additional forms of lipid-lowering therapy, which is also documented in the current guidelines of the European Society of Cardiology and the European Artherosclerosis Society [11] .
The PROVE-IT study showed, for example, that some patients with cardiovascular affection retained a risk of 22.4% to encounter an event in the following 2 years [12] . Furthermore, for Germany, the analysis of the 2L-registry (adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events) allows to critically remark that not all patients with established cardiovascular damage receive adequate statin or other lipid-lowering medication. Some of the LDL-C target values set by current guidelines are met in less than 50% of cases [13] . In light of the cost of the now much differentiated development of new lipid-lowering medications, the capacity of existing substances should be used to its full extent where clinically justifiable.
The anti-sense-oligonucleotide-therapy (mipomersen) acting on the apolipoprotein B100 achieving significant LDL-C and Lp(a)-reduction rates was promising as a new effective medication [14] . Licensing for the European market was, however, declined by the European Medicines Agency (EMA) due to adverse effects. Here, elevated liver function tests and non-alcohol-induced fatty liver development were observed and these conditions led to increased cancellation rates (EMA/177547/2013). The EMA found that the effects of long-term therapy could not be satisfactorily determined by the product developers. Currently, patients exhibiting severe lipometabolic disorder, those remaining at levels of LDL-C >130 mg/dl (3.4 mmol/l) or Lp(a) >60 mg/dl (>120 nmol/l according to WHO-standard SRM B2) despite dietary and medicinal measurements, and those deteriorating from progress of their cardiovascular affection are successfully treated by continuous lipoprotein apheresis, chiefly in weekly intervals [15] .
PCSK9 in the LDL-C Metabolism
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is seemingly an important protein in the LDL-C metabolism. It is, in particular, involved in the regulation of LDL receptor (LDL-R) degradation. The effectivity of exploiting this mode of action of PCSK9 to tackle severe lipometabolic disorder was discovered comparably late. While first reports on mutations in gene sequences of the LDL-R or the apolipoprotein B100 were published in the late 70s and 80s of the 20th century, the work group of Abifadel et al. [16] discovered in 2003, first in 2 French families, a mutation in the gene sequence in PCSK9 related among other things to elevated levels of LDL-C.
To this date, only a few additional PCSK9-mutations are known. The current state can be learnt from http://www. ucl.ac.uk/ldlr. In the follow-up of the findings, numerous experimental investigations on cells and animals were conducted, successfully, elucidating the exact function of PCSK9 with respect to LDL-R ( fig. 1 ). PCSK9 is intracellularly generated, independent of LDL-R and emitted to the cell surface. After PCSK9 has detached from the surface, it binds directly to free LDL-R. If mediated by apolipoprotein B100 an LDL-C molecule attaches to the receptor, the resulting complex including PCSK9 is internalised (endocytosis). Via transport paths, the endosome fusions with one or more lysosomes in such a way, that not only the constituents of the LDL-C molecule are completely decomposed, but the internalised LDL-R is as well decomposed. In case of a genetically caused elevation of PCSK9, the LDL-R concentration in the membrane is significantly reduced, resulting in an increase in LDL-C in serum [17] .
In the process of searching for different mutations of PCSK9 in humans, Cohen et al. [18] found 2 special variations. In these cases, opposed to mutations discovered earlier, where an overexpression of PCSK9 was observed, here PCSK9 was found inactive as a consequence of a socalled nonsense mutation. This refers to the expression of a form of PCSK9 incapable to bind to LDL-R.
These studies furthermore showed for the first time, that the occurrence of PCSK9 without function is indeed connected to an increase in LDL-R and subsequent reduction of S-LDL-R levels by up to 40% as compared to the known mean value. These variations in PCSK9 are related to low rates of cardiovascular events and have exhibited no obvious negative impact on the human organism [19] . Therefore, the development of therapy measures targeting PCSK9 activity and/or the PCSK9-LDL-R binding mechanism has been initiated ( table 1 ) .
This publication focuses on work, trails and their results on the mechanism of monoclonal antibodies (PCSK9-AB) acting on PCSK9. Examples for these have been successfully used in phase-III studies. The principle of action of these substances is a binding to PCSK9 in such a way that subsequent binding to LDL-R is rendered impossible. As a consequence, LDL-R-LDL-C complexes are internalised in the absence of PCSK9, which results in the degradation of LDL-C only, while the LDL-R is 'recycled' and directly returned to the membrane ( fig. 2 ) .
Overview of Study Results
The monoclonal PCSK9-AB Evolocumab (Amgen) and Alirocumab (Sanofi-Regeneron) are both applied in several phase-III studies, for example, DESCARTES, ODYSSEY, for a long term. Another PCSK9-AB, Bococizumab (Pfizer), is close to finish a first phase-III study SPIRE-LDL [20] ( table 1 ) . Existing PCSK9-AB studies show the mechanism described earlier to work very well. Monoclonal antibodies block PCSK9 and induce an increase in the number of LDL-R associated with increased reduction in LDL-C serum concentrations. Following the hypothetical principle of action, it was assumed that the mechanism is particularly effective if LDL-R is retaining its full functionality in the process. In this regard, it is surprising that there are results documenting a reduction in LDL-C by up to 55% even in patients exhibiting mutations of LDL-R, for example, in patients with hyperlipidaemia of heterozygous or homozygous variety [21] . However, these results were obtained from a small sample with large variance in the LDL-C reduction rate. Larger studies are required to derive reliable results and general recommendations. Furthermore, it is noteworthy that a combination of statins and PCSK9-AB seems particularly effective in LDL-C reduction. Patients receiving therapy by PCSK9 and statins show an additional reduction in LDL-C by 50-60% compared to statin mono-therapy. Another interesting fact is that the effect was measured LDL metabolism in the presence of PCSK9. PCSK9 is formed in the hepatocyte and travels to the cell surface to exit into circulation, where it binds to LDL-R on the cell surface. In the presence of PCSK9, the LDL-R pathway is altered: The PCSK9/ LDL-R complex enters the cell via endocytosis. The LDL-R undergoes lysosomal degradation rather than recycling. As a result, fewer receptors are available on the cell surface to remove LDL-C.
independent of the applied statin doses [22] . The possible mechanisms explaining such behaviours are detailed by Zhang et al. [23] . They found that anti-PCSK9 antibody reduces LDL-C on top of a statin and suppresses hepatocyte SREBP-regulated genes. Other lipid-lowering substances do not seem to have additional effects [22] . With respect to the given results, PCSK9 inhibition induced by anti-PCSK9 antibody may have a potential future in patients with heterozygous hypercholesterolemia and in patients suffering from statin myopathy, when the required 274 LDL-C goals could be reached, which in addition may correspond to cardiovascular event reduction [24] . Current studies also report a reduction in Lp(a)-concentration by up to 32% [25] . For particularly high Lp(a)-concentrations, however, the relative reduction by PCSK9-AB observed was only 16%.
For both PCSK9-AB Evolocumab and Alirocumab, current studies show that in combination with statin medication, the required therapy goals for LDL-C levels of <100 mg/dl (<2.6 mmol/l) for patients at risk and <70 mg/dl (<1.8 mmol/l) for high-risk patients, respectively have been reached in more than 80-90% of cases [22, 26] . How these very impressive results impact the rate of cardiovascular events is yet to be determined by ongoing studies (FOURIER respectively ODYSSEY OUTCOMES; US National Library of Medicine; ClinicalTrials.gov 2014; http://clinicaltrials.gov/ct2/show/NCT01764633, US National Library of Medicine; ClinicalTrials.gov 2014; http://clinicaltrials.gov/ct2/show/NCT01663402). On the other hand, the reduction of LDL-C with Evolocumab in homozygous FH was only 23% according to the TESLA-Part B trial [27] .
For both PCSK9-AB good compatibility and little adverse effects of the substances, respectively have been found. Since the medication is administered subcutaneously every 14 days, main side effects are skin irritations (2-9%). The problematic leukocytoclastic vasculitis that has already been reported in conjunction with other monoclonal antibody therapies did occur in a single case of PCSK9-AB therapy [28, 29] . There is no significant difference between a 2 or 4 weeks administration because of an outcome of adverse effects [30] . If the targets are achieved, therapy should be maintained and follow-up sessions should be carried out. PAD = Peripheral artery disease; CVD = cerebrovascular disease; CHD = coronary heart disease; PCSK9i = PCSK9-inhibitor; LA = lipoprotein apheresis.
Conclusion and Outlook
Results of current studies show, that in particular, a combination of PCSK9-AB and statins is independent of the dosage of the statins, suitable to increase the reduction of LDL-C by an additional 50-60%. In contrast, the reduction of Lp(a)-rates is, with a maximum of 32%, significantly lower. Furthermore, it is remarkable that for high Lp(a)-concentrations, yet lower maximum reduction rates of up to 16% have been measured. In patients with the familial homozygous hypercholesterolemia, the PCSK9-AB therapy will remain an additional therapy to LA treatment. With this additional lipid-lowering therapy approach, the combination of statins, LA and PCSK9-AB, it could be possible to reduce LDL-C concentrations to target levels. Whether the approach is furthermore suited to inhibit cardiovascular progress in patients has to be determined by additional research. Should the analysis of ongoing PCSK9-AB studies show a reduction in the rate of cardiovascular events, the use of PCSK9-AB may present an alternative to LA for the treatment of patients with heterozygous hypercholesterolemia or mixed hypercholesterolemia ( fig. 3 ). For patients with elevated Lp(a)-levels and related cardiovascular affections, the so far observed low reduction rates in Lp(a)-concentrations suggest that PCSK9-AB is not an alternative treatment to LA ( fig. 3 ) . However, the antibody treatment may prove to be a valid add-on therapy. Despite the impressive LDL-C reduction rates, studies conducted so far have found only a few adverse effects. Whether the lipid reduction rates do impact the cardiovascular endpoint is yet to be determined by ongoing studies, such as, FOURIER or ODYSSEY OUTCOMES. Another crucial factor that determines the future range of application of this new and thus far very promising therapy approach will be the price of PCSK9-AB. Here, no information is available yet.
